Berkshire Hathaway Sells Stake in UnitedHealth
· news
Berkshire’s Exit: A Misguided Market Reaction to UnitedHealth’s Resurgence
The recent decision by Greg Abel, CEO of Berkshire Hathaway, to sell off the conglomerate’s stake in UnitedHealth Group (UNH) has sent shockwaves through the market. The move, which saw UNH stock decline by over 2%, has left investors wondering whether this is a sign that Warren Buffett’s successor has lost faith in the healthcare giant’s turnaround prospects.
Warren Buffett’s backing was instrumental in propelling UNH to new heights after the company’s dismal performance in 2025. The stock had lost over 30% of its value, ranking as the worst performer on the Dow Jones Industrial Average that year. Berkshire’s entry into the picture marked a turning point for UNH shares, which began to rally as analysts took note of the conglomerate’s trades.
Bill Stone, chief investment officer at Glenview Trust Company, suggests that profit-taking was a plausible motive behind Berkshire’s exit. Morningstar analyst Julie Utterback agrees, characterizing the move as a roster change at Berkshire rather than a fundamental signal about managed care. The broader health insurance sector reported strong first-quarter 2026 results, indicating that UnitedHealth’s operational turnaround is gaining momentum.
UnitedHealth has been making significant strides in its value-based care arm, Optum Health, which now serves over 20 million patients. This segment is poised to drive earnings growth for the company. Management’s focus on reducing friction across the healthcare ecosystem through artificial intelligence should win back both customers and providers. The recent announcement of a 30% reduction in prior authorization volumes and the commitment to processing all prior authorizations in real time by the end of 2027 are tangible signs that UnitedHealth is serious about rebuilding trust with physicians and patients.
Analysts tracking UNH stock forecast free cash flow to improve from $16 billion in 2025 to $30 billion in 2030. If UNH stock is priced at 16.33 times forward FCF, which is in line with its 10-year average, it could deliver a 44% return over the next four years. The average UNH stock price target of $391.16 shows marginal upside of 2.18%, but this should not deter investors who are willing to take a longer-term view.
Berkshire’s exit from UnitedHealth may be a blessing in disguise for investors. By casting aside the perceived “vote of confidence” from Warren Buffett, UNH shares have become more attractive than ever. As the company continues to deliver on its commitments quarter by quarter and with a clear path to margin recovery, it’s hard not to see UNH as one of the more compelling opportunities in large-cap healthcare right now.
With UnitedHealth’s operational momentum building and a clear path forward, this may be the perfect opportunity for investors to buy in on the turnaround story that everyone is talking about. The market’s reaction to Berkshire’s exit has been overblown, and it’s time for investors to take a closer look at UNH shares.
Reader Views
- EKEditor K. Wells · editor
While market analysts have focused on the timing of Berkshire's exit from UnitedHealth, they're overlooking a crucial aspect: the sheer scale of the conglomerate's investment. The sale of 24 million shares translates to a significant chunk of UNH's float, potentially exacerbating volatility in the coming months. As investors weigh their next move, it's worth considering the potential ripple effects on broader healthcare markets and how other players might capitalize on Berkshire's reduced stake.
- ADAnalyst D. Park · policy analyst
It's too simplistic to view Berkshire Hathaway's sale of its UnitedHealth stake as mere profit-taking or a benign roster change at the conglomerate. The timing and scale of this move suggest that Abel may be signaling a deeper concern about the healthcare industry's regulatory landscape. With Biden's administration pushing for increased price transparency and a re-examination of the 'No Surprises Act', investors should carefully monitor any future Berkshire moves in the sector, as they often foreshadow shifts in market sentiment.
- CSCorrespondent S. Tan · field correspondent
While the sell-off of Berkshire's stake in UnitedHealth Group may seem like a ominous sign, investors should be cautious not to read too much into it. The fact that Berkshire has been gradually reducing its stake over time suggests that this exit is more about profit-taking than a loss of faith in UNH's turnaround prospects. What's worth watching now is how the company will continue to execute on its value-based care strategy, particularly with Optum Health's impressive growth trajectory and AI-driven efforts to streamline prior authorizations.